RS61742B1 - Imunomodulatori za pet-snimanje - Google Patents

Imunomodulatori za pet-snimanje

Info

Publication number
RS61742B1
RS61742B1 RS20210499A RSP20210499A RS61742B1 RS 61742 B1 RS61742 B1 RS 61742B1 RS 20210499 A RS20210499 A RS 20210499A RS P20210499 A RSP20210499 A RS P20210499A RS 61742 B1 RS61742 B1 RS 61742B1
Authority
RS
Serbia
Prior art keywords
compound
subject
ethoxy
tissues
disease
Prior art date
Application number
RS20210499A
Other languages
English (en)
Serbian (sr)
Inventor
David J Donnelly
Kenneth M Boy
Yunhui Zhang
Joonyoung Kim
Adrienne Pena
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of RS61742B1 publication Critical patent/RS61742B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/12—Arrangements for detecting or locating foreign bodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RS20210499A 2016-05-19 2017-05-17 Imunomodulatori za pet-snimanje RS61742B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338872P 2016-05-19 2016-05-19
EP17728696.0A EP3458111B1 (en) 2016-05-19 2017-05-17 Pet-imaging immunomodulators
PCT/US2017/033004 WO2017201111A1 (en) 2016-05-19 2017-05-17 Pet-imaging immunomodulators

Publications (1)

Publication Number Publication Date
RS61742B1 true RS61742B1 (sr) 2021-05-31

Family

ID=59021563

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210499A RS61742B1 (sr) 2016-05-19 2017-05-17 Imunomodulatori za pet-snimanje

Country Status (25)

Country Link
US (2) US11103605B2 (enExample)
EP (2) EP3827849A1 (enExample)
JP (1) JP6953444B2 (enExample)
KR (1) KR102378288B1 (enExample)
CN (1) CN109414514B (enExample)
AU (1) AU2017268291B2 (enExample)
BR (1) BR112018073642A2 (enExample)
CA (1) CA3024844A1 (enExample)
CY (1) CY1124241T1 (enExample)
DK (1) DK3458111T3 (enExample)
EA (1) EA038019B1 (enExample)
ES (1) ES2864091T3 (enExample)
HR (1) HRP20210644T8 (enExample)
HU (1) HUE054306T2 (enExample)
IL (1) IL262962B (enExample)
LT (1) LT3458111T (enExample)
MA (1) MA53402A (enExample)
MX (1) MX2018014028A (enExample)
PL (1) PL3458111T3 (enExample)
PT (1) PT3458111T (enExample)
RS (1) RS61742B1 (enExample)
SG (1) SG11201810177VA (enExample)
SI (1) SI3458111T1 (enExample)
SM (1) SMT202100238T1 (enExample)
WO (1) WO2017201111A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
RS67792B1 (sr) 2016-12-01 2026-03-31 Regeneron Pharma Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
BR112019012986A2 (pt) * 2016-12-23 2019-12-03 Univ Johns Hopkins imageamento de tumores e de células imunes com base na expressão de pd-l1
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
CN110997698B (zh) 2017-06-23 2023-12-26 百时美施贵宝公司 充当pd-1拮抗剂的免疫调节剂
CN110997013B (zh) 2017-07-24 2022-09-20 瑞泽恩制药公司 抗cd8抗体和其用途
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators
CN110504017B (zh) * 2019-07-30 2022-06-10 哈尔滨医科大学 一种示踪剂的制备和使用方法
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
CN114929728A (zh) 2020-01-06 2022-08-19 百时美施贵宝公司 免疫调节剂
CN115485288A (zh) * 2020-03-16 2022-12-16 百时美施贵宝公司 免疫调节剂
KR20220161407A (ko) 2020-03-30 2022-12-06 브리스톨-마이어스 스큅 컴퍼니 면역조정제
US12159403B2 (en) * 2021-06-18 2024-12-03 The United States Government As Represented By The Department Of Veteran Affairs Combination of features from biopsies and scans to predict prognosis in SCLC
AU2023395853A1 (en) * 2022-12-12 2025-06-19 Merck Sharp & Dohme Llc Cyclic peptides as pet imaging agents of granzyme b

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5128119A (en) 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US5328679A (en) 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5746996A (en) 1994-06-03 1998-05-05 Immunomedics, Inc. Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5753206A (en) 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
AU717020B2 (en) 1996-05-03 2000-03-16 Immunomedics Inc. Targeted combination immunotherapy of cancer
ATE380038T1 (de) 1996-07-12 2007-12-15 Immunomedics Inc Radiometall-bindende peptide analoge
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
DE69837095T2 (de) 1997-09-03 2007-11-22 Immunomedics, Inc. Fluorierung von proteinen und peptiden für positronemissionstomographie
US9090668B2 (en) 2007-03-26 2015-07-28 The University Of Tokyo Process for synthesizing cyclic peptide compound
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 N−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
JP6206943B2 (ja) 2010-12-03 2017-10-04 国立大学法人 東京大学 ペプチドライブラリーの製造方法、ペプチドライブラリー、及びスクリーニング方法
EP2717895A1 (en) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013010573A1 (en) * 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
CN104245726A (zh) 2012-03-29 2014-12-24 奥瑞基尼探索技术有限公司 来自人pd1的bc环的免疫调节环状化合物
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo pH依存的に標的分子に結合するペプチドのスクリーニング方法
MX355396B (es) 2012-06-06 2018-04-18 Polyphor Ag Peptido - mimeticos de la horquilla beta.
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
KR20150131269A (ko) 2013-03-15 2015-11-24 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
MX2016002970A (es) 2013-09-06 2016-10-07 Aurigene Discovery Tech Ltd Compuestos peptidomimeticos ciclicos como inmunomoduladores.
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
MA40132B1 (fr) 2014-09-11 2019-04-30 Bristol Myers Squibb Co Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
JP6622814B2 (ja) * 2014-11-25 2019-12-18 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company イメージングのための新規pd−l1結合ポリペプチド
WO2016086036A2 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of biologics
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
KR102526034B1 (ko) 2016-11-07 2023-04-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
CN110997698B (zh) 2017-06-23 2023-12-26 百时美施贵宝公司 充当pd-1拮抗剂的免疫调节剂
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators

Also Published As

Publication number Publication date
MA53402A (fr) 2021-06-02
HRP20210644T1 (hr) 2021-05-28
IL262962A (en) 2018-12-31
PT3458111T (pt) 2021-04-09
JP6953444B2 (ja) 2021-10-27
DK3458111T3 (da) 2021-04-26
EA038019B1 (ru) 2021-06-23
HUE054306T2 (hu) 2021-08-30
EP3827849A1 (en) 2021-06-02
CN109414514B (zh) 2022-03-11
US20210386876A1 (en) 2021-12-16
CY1124241T1 (el) 2022-07-22
ES2864091T3 (es) 2021-10-13
BR112018073642A2 (pt) 2019-02-26
SI3458111T1 (sl) 2021-07-30
MX2018014028A (es) 2019-04-04
CN109414514A (zh) 2019-03-01
US11103605B2 (en) 2021-08-31
SG11201810177VA (en) 2018-12-28
KR20190009330A (ko) 2019-01-28
US20190117801A1 (en) 2019-04-25
HRP20210644T8 (hr) 2021-06-25
LT3458111T (lt) 2021-05-25
IL262962B (en) 2020-04-30
CA3024844A1 (en) 2017-11-23
EP3458111A1 (en) 2019-03-27
JP2019520328A (ja) 2019-07-18
KR102378288B1 (ko) 2022-03-23
AU2017268291A1 (en) 2019-01-17
EA201892635A1 (ru) 2019-04-30
WO2017201111A1 (en) 2017-11-23
SMT202100238T1 (it) 2021-05-07
EP3458111B1 (en) 2021-03-03
AU2017268291B2 (en) 2022-09-29
PL3458111T3 (pl) 2021-06-28

Similar Documents

Publication Publication Date Title
US20210386876A1 (en) Pet-imaging immunomodulators
US20220202966A1 (en) Positron emitting radionuclide labeled peptides for human upar pet imaging
EP3223866B1 (en) Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain
EP4537851A1 (en) Trifunctional compound and use thereof
US20160303258A1 (en) Compounds and compositions for imaging gcc-expressing cells
CN115286693B (zh) 针对癌胚抗原相关细胞黏附分子ceacam6的肿瘤靶向肽及其应用
Zhu et al. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy
Lindeman et al. FAP radioligand linker optimization improves tumor dose and tumor-to-healthy organ ratios in 4T1 syngeneic model
Lamba et al. Synthetic 18F labeled biomolecules that are selective and promising for PET imaging: Major advances and applications
WO2013106824A1 (en) Epherin receptor targeting agents
Liu et al. Development of an albumin-based PSMA probe with prolonged half-life
Oum et al. A benzenesulfonamide derivative as a novel PET radioligand for CXCR4
CN119775367B (zh) 一种靶向Nectin-4的双环肽核素配体、探针及其制备方法与应用
Prasanphanich et al. The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals
CN117813326A (zh) 基于放射的导蛋白-1的检测、伴随测试和治疗方法
Zeglis et al. Radiopharmaceuticals for imaging in oncology with special emphasis on positron-emitting agents
Sun et al. Synthesis and biological evaluation of 68Ga-DOTA-AngII as a radiotracer for PET/MR imaging of hepatocellular carcinoma
CN103275188B (zh) 放射性标记t140类多肽化合物及其制备方法和应用
Verena Development of bispecific prostate-specific membrane antigen/fibroblast activation protein (PSMA/FAP)-targeting radiotracers for prostate cancer imaging
Pang et al. 68Ga-DOTA-Neratinib: A novel small-molecule PET tracer for breast cancer imaging
AU2024344671A1 (en) Functionalized peptides for in-vivo addressing of pd-l1 expression
WO2026083399A1 (en) Conjugates and use of same for theranostics
CN114081969A (zh) 标记的小分子抗体、及其标记方法和应用
CN110551075A (zh) 放射性标记亚谷氨基酸类化合物及其在制备pet显像剂的应用
Montemagno et al. Preclinical evaluation of novel mesothelin-specific ligands for SPECT imaging of Triple Negative Breast Cancer. Author names and affiliations.